Lexaria Bioscience Corp Stock Today
| LEXX Stock | USD 2.09 0.04 1.88% |
Performance0 of 100
| Odds Of DistressOver 54
|
Lexaria Bioscience is trading at 2.09 as of the 28th of November 2024; that is 1.88% down since the beginning of the trading day. The stock's open price was 2.13. Lexaria Bioscience has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Lexaria Bioscience Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2006 | Category Healthcare | Classification Health Care |
Lexaria Bioscience Corp. operates as a biotechnology company. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. The company has 17.45 M outstanding shares of which 277.08 K shares are now shorted by private and institutional investors with about 2.34 trading days to cover. More on Lexaria Bioscience Corp
Moving together with Lexaria Stock
| 0.77 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.91 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lexaria Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lexaria Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Director | John MSc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLexaria Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexaria Bioscience's financial leverage. It provides some insight into what part of Lexaria Bioscience's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexaria Bioscience Corp (LEXX) is traded on NASDAQ Exchange in USA. It is located in 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 and employs 5 people. Lexaria Bioscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.17 M. Lexaria Bioscience Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 17.45 M outstanding shares of which 277.08 K shares are now shorted by private and institutional investors with about 2.34 trading days to cover.
Lexaria Bioscience Corp currently holds about 7.34 M in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.23.
Check Lexaria Bioscience Probability Of Bankruptcy
Ownership AllocationLexaria Bioscience Corp maintains a total of 17.45 Million outstanding shares. Lexaria Bioscience Corp secures 7.0 % of its outstanding shares held by insiders and 6.0 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lexaria Ownership Details
Lexaria Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wealth Enhancement Advisory Services, Llc | 2024-09-30 | 13.8 K | |
| Royal Bank Of Canada | 2024-06-30 | 7.3 K | |
| Oakworth Capital Inc | 2024-09-30 | 5 K | |
| Tower Research Capital Llc | 2024-06-30 | 3.4 K | |
| Wells Fargo & Co | 2024-06-30 | 3.3 K | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 2.3 K | |
| Aspire Private Capital, Llc | 2024-09-30 | 400 | |
| Mather Group, Inc. | 2024-06-30 | 100.0 | |
| Bank Of America Corp | 2024-06-30 | 96.0 | |
| Invenomic Capital Management, Lp | 2024-09-30 | 475.8 K | |
| Geode Capital Management, Llc | 2024-09-30 | 150.4 K |
Lexaria Bioscience Historical Income Statement
Lexaria Stock Against Markets
Lexaria Bioscience Corporate Management
| Christopher Bunka | Chairman CEO | Profile | |
| Vanessa Carle | Head Legal | Profile | |
| Philip Ainslie | Advisor Consultant | Profile | |
| Nelson CPA | Chief Officer | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Richard Christopher | Chief Officer | Profile |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.